London Co. of Virginia Has $11.01 Million Position in Certara, Inc. $CERT

London Co. of Virginia lowered its position in Certara, Inc. (NASDAQ:CERT) by 19.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,249,237 shares of the company’s stock after selling 305,754 shares during the quarter. London Co. of Virginia owned 0.78% of Certara worth $11,006,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. increased its stake in shares of Certara by 2,733.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after buying an additional 2,870 shares during the period. Osaic Holdings Inc. increased its stake in shares of Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after buying an additional 4,930 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Certara in the second quarter valued at approximately $83,000. Finally, Curated Wealth Partners LLC acquired a new position in shares of Certara in the fourth quarter valued at approximately $89,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Price Performance

CERT stock opened at $6.05 on Wednesday. The stock has a market capitalization of $941.20 million, a PE ratio of -60.50 and a beta of 1.49. The company’s 50-day moving average is $5.59 and its 200-day moving average is $7.12. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. Certara, Inc. has a 1 year low of $4.45 and a 1 year high of $13.88.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The company had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.Certara’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period last year, the company earned $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Equities research analysts expect that Certara, Inc. will post 0.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on CERT shares. Stephens lowered their price objective on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Craig Hallum lowered their price objective on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th. KeyCorp lowered their price objective on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Monday, April 13th. Barclays decreased their target price on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Finally, BMO Capital Markets decreased their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.85.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.